GlassScriptPhysician profile
Abubaker Hassan
NPI 1568846822
$3,301.14
in general payments reported to CMS, 2019-2025
17 companies · $2,622 in 2025
The $2,622 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.93 · 2024: $660 · 2025: $2,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,037 · Travel and Lodging: $1,107 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,037.13 |
| Travel and Lodging | $1,107.32 |
| Education | $137.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,136.29 | 2025 | Spiration Valve System |
| Glaxosmithkline, LLC. | $559.22 | 2024-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $490.26 | 2024-2025 | Fasenra, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $327.70 | 2024-2025 | Dupixent |
| Genzyme Corporation | $323.14 | 2024-2025 | |
| Viatris Specialty LLC | $94.05 | 2025 | Yupelri |
| Insmed, INC. | $65.07 | 2024-2025 | Arikayce |
| Mylan Specialty L.P. | $47.43 | 2024 | Yupelri |
| Verona Pharma, INC. | $46.81 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $45.90 | 2025 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.23 | 2024-2025 | Jascayd, Ofev |
| Ani Pharmaceuticals, INC. | $26.65 | 2025 | Purified Cortrophin Gel |
| Philips North America LLC | $20.82 | 2025 | Vest Therapy Und |
| Amgen INC. | $19.08 | 2024 | Tezspire |
| Gilead Sciences, INC. | $18.93 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $18.53 | 2024 | Xolair |
| Pulmonx Corporation | $18.03 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abubaker Hassan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.